Trending Topic

5 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

touchDERMATOLOGY coverage from EADV 2024: Twice-daily continuous application of ruxolitinib cream, a topical selective JAK1/JAK2 inhibitor, has been reported to be safe and effective in treating children with mild to moderate atopic dermatitis (AD) over an 8-week period in the TRuE-AD studies.1,2 In this interview, we talk with Dr Amy Paller from the Northwestern University […]

Specialities

touchDERMATOLOGY touchDERMATOLOGY

Register Now!

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

  • Save your progress for video
  • Keep track of your CME credits
  • Add personalised learning notes
  • Receive updates from course leaders and faculty
  • Be the first to hear about new and exciting interactive learning opportunities
Close Popup